<div><div></div><div><span><p><span>Rafael Holdings, Inc. reported third-quarter 2026 results showing revenue of $179K and a net loss of ($4.23M), or diluted EPS of ($0.08), compared with revenue of $362K and a net loss of ($4.78M), or EPS of ($0.19), in the prior-year quarter.</span></p><p><strong><span>Financial Highlights</span></strong></p><div><table><tbody><tr><td><span>Metric</span></td><td><span>Current quarter</span></td><td><span>Prior year quarter</span></td><td><span>YoY change</span></td></tr><tr><td><span>Revenue¹</span></td><td><span>$179K</span></td><td><span>$362K</span></td><td><span>(50.6%)</span></td></tr><tr><td><span>Net income²</span></td><td><span>($4.23M)</span></td><td><span>($4.78M)</span></td><td><span>11.6%</span></td></tr><tr><td><span>Diluted EPS³</span></td><td><span>($0.08)</span></td><td><span>($0.19)</span></td><td><span>57.9%</span></td></tr></tbody></table></div><p><em><span>¹ Reported as “Total revenue”. ² Reported as “Net loss attributable to Rafael Holdings, Inc.”. ³ Reported as “Loss per share attributable to common stockholders”.</span></em></p><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Lead product advancement: Completed the Cyclo merger and consolidated Trappsol® Cyclo™ as the company's lead candidate, advancing a pivotal Phase 3 trial for Niemann‑Pick disease type C1 (NPC1).</span></li><li><span>Revenue mix shift: Healthcare product revenue rose year over year for the nine-month period driven by Cyclo specialty chemicals, while Infusion Technology revenues declined following an asset sale.</span></li><li><span>R&amp;D acceleration: Increased R&amp;D spending to support Cyclo Phase 3 and ongoing clinical development activities.</span></li><li><span>Portfolio focus: Management is evaluating non-core holdings to concentrate resources on Trappsol® Cyclo™ and strategic therapeutic investments.</span></li><li><span>Regulatory milestone: Rafael Medical Devices received FDA 510(k) substantial equivalence clearance for the VECTR System for minimally invasive ligament/fascia release.</span></li></ul><p><span>Original SEC Filing: </span>Rafael Holdings, Inc. [ RFL ] - 10-Q - Jun. 11, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

<p>Rafael Holdings reported Q3 2026 revenue of $179K, down 50.6% YoY, with a net loss of $4.23M and diluted EPS of ($0.08). The company advanced its lead candidate Trappsol Cyclo into Phase 3 trials for NPC1 and received FDA clearance for the VECTR System. R&D spending increased to support clinical development, while management evaluates non-core assets to focus on strategic therapeutic investments.</p>

Rafael Holdings, Inc. 3Q 2026: Revenue $179K, EPS ($0.08) — 10-Q Summary